Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases - 01/06/19
Highlights |
• | IFN-γ response to QFT-P is lower in IMID-LTBI compared to LTBI without IMID. |
• | IMID status does not impact the ability to respond simultaneously to TB1 and TB2. |
• | Similar proportion of discordant TB1 and TB2 results in IMID-LTBI and LTBI. |
• | IMID-LTBI patients have a high probability to have QFT-P results in the grey zone range. |
• | Type of IMID therapy does not impact the distribution of IFNγ results to QFT-P. |
Summary |
Objectives |
Screening for latent tuberculosis infection (LTBI) diagnosis is mandatory in patients with immune-mediated inflammatory diseases (IMID) requiring biologics. QuantiFERON-TB-Plus (QFT-P), an LTBI diagnostic test, measures IFN-γ after M. tuberculosis-stimulation in TB1 and TB2 tubes in which a “CD4” or a “CD4 and CD8” response is respectively elicited. Aim of this study is to compare the response to QFT-P of IMID-LTBI patients candidates to a new biological therapy vs LTBI-subjects without IMID.
Methods |
We prospectively enrolled 167 subjects: 61 IMID-LTBI and 106 NON-IMID-LTBI.
Results |
All subjects were mitogen-responders. IFN-γ production was significantly lower in IMID-LTBI-patients compared to NON-IMID-LTBI-subjects. We observed discordant TB1 and TB2 results in 6.5% of IMID-LTBI-patients and in 8% of NON-IMID-LTBI-subjects. Applying a logistic regression analysis, we found that IMID-LTBI patients had a higher probability (TB1 stimulation OR 3.32; TB2 stimulation OR 4.33) to have IFNγ results ≤0.7 IU/mL compared to NON-IMID-LTBI-subjects. Interestingly, IMID-treatment did not interfere with the distribution of IFNγ-values.
Conclusions |
These results indicate that IMID-LTBI-patients have a low IFN-γ response to QFT-P, a high proportion of results ranging in the grey zone and a distribution of IFNγ-values independent from the IMID-treatment. These results are important for the management of LTBI screening in IMID patients.
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, LTBI, IMID, IGRA, QuantiFERON-TB-Plus, Biological therapy, Anti-TNFα
Plan
Vol 79 - N° 1
P. 15-23 - juillet 2019 Retour au numéro
Article précédent
- High diversity of invasive Haemophilus influenzae isolates in France and the emergence of resistance to third generation cephalosporins by alteration of ftsI gene
- Ala-Eddine Deghmane, Eva Hong, Sara Chehboub, Aude Terrade, Michaël Falguières, Morgan Sort, Odile Harrison, Keith A. Jolley, Muhamed-Kheir Taha
- The incremental value of bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in a high-burden urban setting
- Ping Xu, Peijun Tang, Huafeng Song, Jing Zhao, Hui Chen, Jing Xue, Yunxia Zhai, Yu Pang, Meiying Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?